SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

Never Miss a Story

Sign up for email alerts

 

More Industry Headlines

Companies develop pediatric medical devices to compete for $50,000 prize Will the smallest of patients finally have more options?

New imaging method may detect cancer earlier Will shortwave infrared be a bright spot?

Siemens AAMI 2014 CMS debate video released See a video of the debate on CMS's imaging equipment maintenance edict from December 2013

Technology uses extremely cold temperatures to treat breast cancer Multi-center trial enrolls first patients

Samsung's tablet ultrasound can diagnose patients en route to hospital The technology can prove crucial when seconds matter

Ultrasound-powered chip monitors diseases and delivers therapies May be able to study nervous system and treat Parkinson's symptoms

Celgene invests in Sequenta's MRD test Test will participate in trials to create blood cancer medicine

AFT calls for improved Ebola hospital protocols Meanwhile, 43 people in Texas are removed from Ebola watch list

Americans with insurance still not going to doctor Will making cost and quality information transparent be the solution?

Mass. health care cost transparency law underperforming Pricing still murky after transparency law introduced

Hologic wraps up $3.8 billion Gen-Probe buy

by Brendon Nafziger , DOTmed News Associate Editor
Hologic said Wednesday that it wrapped up its nearly $3.8 billion cash purchase of molecular diagnostics company Gen-Probe Inc., in line with the company's earlier projections.

On an earnings call this week, the publicly traded women's health medical device company indicated that it expected the deal, first announced in April, to finish by Aug. 1.

Story Continues Below Advertisement

Delivering on Dose Reduction Promises

Dr. Steven Mendelsohn of Zwanger-Pesiri Radiology, explains his commitment to dose reduction and why he believes a change in attitudes will be driven by patients rather than radiology professionals. Click to read more>>>



Gen-Probe, based in San Diego, makes tests for STDs and the West Nile Virus, among other conditions.

Gen-Probe's shareholders voted to approve the transaction on Tuesday. Shareholders will receive $82.75 in cash for each share.

Hologic expects the deal to add 20 cents to its adjusted earnings per share for the next fiscal year. The Bedford, Mass.-based company also hopes to realize $75 million in "cost synergies" over the next three years.

This week, while announcing third quarter financial results, Hologic also revealed that it was nearly halfway to its sales goal for its 3-D mammography system, the first of its kind cleared for sale in the United States.

Related:


Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

You Must Be Logged In To Post A Comment

Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2014 DOTmed.com, Inc.
ALL RIGHTS RESERVED